<?xml version='1.0' encoding='utf-8'?>
<document id="27328703"><sentence text="A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy."><entity charOffset="46-56" id="DDI-PubMed.27328703.s1.e0" text="lurasidone" /><entity charOffset="61-71" id="DDI-PubMed.27328703.s1.e1" text="atazanavir" /><pair ddi="false" e1="DDI-PubMed.27328703.s1.e0" e2="DDI-PubMed.27328703.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27328703.s1.e0" e2="DDI-PubMed.27328703.s1.e1" /></sentence><sentence text="The cytochrome P450 isoform that is primarily involved in the metabolism of the antipsychotic lurasidone is CYP3A4"><entity charOffset="94-104" id="DDI-PubMed.27328703.s2.e0" text="lurasidone" /></sentence><sentence text=" Drugs that inhibit or induce this enzyme would then be expected to increase or decrease serum concentrations of lurasidone, respectively"><entity charOffset="113-123" id="DDI-PubMed.27328703.s3.e0" text="lurasidone" /></sentence><sentence text=" Atazanavir, an HIV-1 protease inhibitor, has demonstrated to be an inhibitor of CYP3A4 and would be expected to increase the exposure of any drug metabolized by this enzyme"><entity charOffset="1-11" id="DDI-PubMed.27328703.s4.e0" text="Atazanavir" /></sentence><sentence text=" We report a case of an atazanavir-precipitated drug-drug interaction that led to elevated serum concentrations of lurasidone and associated clinical symptoms of drug toxicity"><entity charOffset="24-34" id="DDI-PubMed.27328703.s5.e0" text="atazanavir" /><entity charOffset="115-125" id="DDI-PubMed.27328703.s5.e1" text="lurasidone" /><pair ddi="false" e1="DDI-PubMed.27328703.s5.e0" e2="DDI-PubMed.27328703.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27328703.s5.e0" e2="DDI-PubMed.27328703.s5.e1" /></sentence><sentence text="" /></document>